NET PROFIT (x1000 NOK)
PCI Biotech Holding ASA
Closing information (x1000 NOK)
| Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
160
|
359
|
3,151 |
| Earnings before taxes |
-20,315
|
-55,095
|
-88,391 |
| Total assets |
44,051
|
63,481
|
135,978 |
| Current assets |
43,754
|
62,758
|
128,318 |
| Current liabilities |
4,974
|
5,753
|
20,910 |
| Equity capital |
39,042
|
57,402
|
113,793 |
| - share capital |
1,119
|
111,979
|
111,979 |
Financial ratios
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Solvency |
88.6%
|
90.4%
|
83.7% |
| Turnover per employee | |||
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-45.8%
|
-86.2%
|
-62.7% |
| Current ratio |
879.7%
|
1090.9%
|
613.7% |
| Return on equity (ROE) |
-52.0%
|
-96.0%
|
-77.7% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.